Garry W. Buchko

Dr. Garry W. Buchko

orcid

Research Focus & Metrics

Academic Career Length

39Years (1988-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
14 September 2016 in Nature
Verified
Journal Article
Open access
PDF file
GBGaurav Bhardwaj
Gaurav Bhardwaj
VMVikram Khipple Mulligan
Vikram Khipple Mulligan
CBChristopher D. Bahl
Christopher D. Bahl
JGJason M. Gilmore
Jason M. Gilmore
PHPeta Harvey
Peta Harvey
DBDavid Baker
David Baker
Naturally occurring, pharmacologically active peptides constrained with covalent crosslinks generally have shapes that have evolved to fit precisely into binding pockets on their targets. Such peptides can have excellent pharmaceutical properties, combining the stability and tissue penetration of small-molecule drugs with the specificity of much larger protein therapeutics. The ability to design constrained peptides with precisely specified tertiary structures would enable the design of shape-complementary inhibitors of arbitrary targets. Here we describe the development of computational methods for accurate de novo design of conformationally restricted peptides, and the use of these methods to design 18–47 residue, disulfide-crosslinked peptides, a subset of which are heterochiral and/or N–C backbone-cyclized. Both genetically encodable and non-canonical peptides are exceptionally stable to thermal and chemical denaturation, and 12 experimentally determined X-ray and NMR structures are nearly identical to the computational design models. The computational design methods and stable scaffolds presented here provide the basis for development of a new generation of peptide-based drugs.

31 May 2010 in Small
Verified
Journal Article
Closed access
PDF file
ZTZhiwen Tang
Zhiwen Tang
HWHong Wu
Hong Wu
JCJohn R. Cort
John R. Cort
GBGarry W. Buchko
Garry W. Buchko
YZYouyu Zhang
Youyu Zhang
YLYuehe Lin
Yuehe Lin

1 August 1994 in Journal of the American Chemical Society
Verified
Journal Article
Closed access
JCJean Cadet
Jean Cadet
MBMaurice Berger
Maurice Berger
GBGarry W. Buchko
Garry W. Buchko
PJPrakash C. Joshi
Prakash C. Joshi
SRSebastien Raoul
Sebastien Raoul
JRJean-Luc Ravanat
Jean-Luc Ravanat

1 March 2015 in Tuberculosis
Verified
Journal Article
Closed access
LBLoren Baugh
Loren Baugh
IPIsabelle Phan
Isabelle Phan
DBDarren W. Begley
Darren W. Begley
MCMatthew C. Clifton
Matthew C. Clifton
BABrianna Armour
Brianna Armour
PMPeter Myler
Peter Myler

4 December 2013 in PLOS ONE
Verified
Journal Article
Open access
PDF file
Uma Shankar SagaramUma Shankar Sagaram
Uma Shankar Sagaram
KEKaoutar El-Mounadi
Kaoutar El-Mounadi
GBGarry W. Buchko
Garry W. Buchko
HBHoward R Berg
Howard R Berg
JKJagdeep Kaur
Jagdeep Kaur
Dilip ShahDilip Shah
Dilip Shah
MtDef4 is a 47-amino acid cysteine-rich evolutionary conserved defensin from a model legume Medicago truncatula. It is an apoplast-localized plant defense protein that inhibits the growth of the ascomycetous fungal pathogen Fusarium graminearum in vitro at micromolar concentrations. Little is known about the mechanisms by which MtDef4 mediates its antifungal activity. In this study, we show that MtDef4 rapidly permeabilizes fungal plasma membrane and is internalized by the fungal cells where it accumulates in the cytoplasm. Furthermore, analysis of the structure of MtDef4 reveals the presence of a positively charged γ-core motif composed of β2 and β3 strands connected by a positively charged RGFRRR loop. Replacement of the RGFRRR sequence with AAAARR or RGFRAA abolishes the ability of MtDef4 to enter fungal cells, suggesting that the RGFRRR loop is a translocation signal required for the internalization of the protein. MtDef4 binds to phosphatidic acid (PA), a precursor for the biosynthesis of membrane phospholipids and a signaling lipid known to recruit cytosolic proteins to membranes. Amino acid substitutions in the RGFRRR sequence which abolish the ability of MtDef4 to enter fungal cells also impair its ability to bind PA. These findings suggest that MtDef4 is a novel antifungal plant defensin capable of entering into fungal cells and affecting intracellular targets and that these processes are mediated by the highly conserved cationic RGFRRR loop via its interaction with PA.

31 January 2013 in PLOS ONE
Verified
Journal Article
Open access
PDF file
LBLoren Baugh
Loren Baugh
LGLarry A. Gallagher
Larry A. Gallagher
RPRapatbhorn Patrapuvich
Rapatbhorn Patrapuvich
MCMatthew C. Clifton
Matthew C. Clifton
AGAnna S. Gardberg
Anna S. Gardberg
WVWesley C. Van Voorhis
Wesley C. Van Voorhis
The genus Burkholderia includes pathogenic gram-negative bacteria that cause melioidosis, glanders, and pulmonary infections of patients with cancer and cystic fibrosis. Drug resistance has made development of new antimicrobials critical. Many approaches to discovering new antimicrobials, such as structure-based drug design and whole cell phenotypic screens followed by lead refinement, require high-resolution structures of proteins essential to the parasite. We experimentally identified 406 putative essential genes in B. thailandensis, a low-virulence species phylogenetically similar to B. pseudomallei, the causative agent of melioidosis, using saturation-level transposon mutagenesis and next-generation sequencing (Tn-seq). We selected 315 protein products of these genes based on structure-determination criteria, such as excluding very large and/or integral membrane proteins, and entered them into the Seattle Structural Genomics Center for Infection Disease (SSGCID) structure determination pipeline. To maximize structural coverage of these targets, we applied an “ortholog rescue” strategy for those producing insoluble or difficult to crystallize proteins, resulting in the addition of 387 orthologs (or paralogs) from seven other Burkholderia species into the SSGCID pipeline. This structural genomics approach yielded structures from 31 putative essential targets from B. thailandensis, and 25 orthologs from other Burkholderia species, yielding an overall structural coverage for 49 of the 406 essential gene families, with a total of 88 depositions into the Protein Data Bank. Of these, 25 proteins have properties of a potential antimicrobial drug target i.e., no close human homolog, part of an essential metabolic pathway, and a deep binding pocket. We describe the structures of several potential drug targets in detail. This collection of structures, solubility and experimental essentiality data provides a resource for development of drugs against infections and diseases caused by Burkholderia. All expression clones and proteins created in this study are freely available by request.